Peer-reviewed veterinary case report
Plasma adrenomedullin levels rise in dogs with mitral valve disease
By Kanno, Nobuyuki et al.·Published in The Journal of veterinary medical science·2012·Department of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Plasma adrenomedullin concentration in dogs with myxomatous mitral valvular disease.
- Species:
- dog
Plain-English summary
A group of dogs with myxomatous mitral valvular disease (MMVD), a common heart condition, had higher levels of a substance called adrenomedullin in their blood compared to healthy dogs. The amount of adrenomedullin increased with the severity of heart failure, which can help veterinarians assess how serious the dog's condition is. This study suggests that measuring adrenomedullin could be useful for diagnosing heart failure in dogs. If your dog has MMVD, discussing this test with your veterinarian might provide valuable information about their heart health.
People also search for: dog heart disease symptoms · myxomatous mitral valvular disease treatment · adrenomedullin test for dogs
Abstract
Adrenomedullin (AM), a peptide identified to have vasodilating and natriuretic effects, is involved in the regulation of the cardiovascular system. To evaluate plasma AM concentration in dogs with myxomatous mitral valvular disease (MMVD), and to investigate the associations between the concentrations of plasma AM and natriuretic peptides and the echocardiographic data, we evaluated plasma AM concentrations in 31 healthy control dogs and 57 dogs with MMVD. Plasma AM concentrations in dogs with MMVD were higher than that in the control subjects. The plasma AM concentration increased in conjunction with the severity of heart failure according to the International Small Animal Cardiac Health Council (ISACHC). The AM concentrations were 25.1 ± 5.0 fmol/ml (ISACHC class Ia), 29.9 ± 11.0 fmol/ml (ISACHC class Ib), 43.4 ± 19.8 fmol/ml (ISACHC class II) and 73.5 ± 21.7 fmol/ml (ISACHC class III) and 7.5 ± 5.1 fmol/ml (control group), respectively. The receiver operating characteristic curve indicated an area of 0.93 (95% CI, 0.8801-0.9889; <0.0001), a cutoff value of 30.5 fmol/ml, a sensitivity of 87.1%, and a specificity of 82.5% for the determination of congestive heart failure. Plasma AM concentrations correlated with atrial natriuretic peptide concentrations, LA/Ao ratio, and left ventricular diameter. In conclusion, AM may be a potential diagnostic marker for canine MMVD and possibly plays a pathophysiological role in collaboration with the other neurohumoral factors such as natriuretic peptides.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22240987/